Digital biomarkers Ad Scientiam specializes in digital biomarkers for continuous real-world monitoring of serious diseases, presenting a clear opportunity to position solutions for pharma and hospitals seeking remote patient monitoring and data-driven outcomes.

Healthcare partnerships Existing collaborations with major hospitals and pharma players (Biogen, Janssen, Roche, Pfizer, Vertex, Novartis; Brain Institute) indicate a proven path for joint development, studies, and procurement partnerships that can be expanded in neuroscience and rare diseases.

MSCOPILOT expansion MSCOPILOT is CE-marked for self-assessment in multiple sclerosis; recent US deployment in MS-FLOWER signals a scalable model to integrate into routine care, suggesting opportunities for global expansion and payer-supported trials.

Global clinical studies Active and upcoming international studies on MS progression and NMOSD demonstrate demand for digital biomarker platforms in multinational cohorts, creating avenues for study sponsorship, data services, and regulatory-aligned endpoints.

Financial resilience While revenue is modest, a growth capital fund has been engaged to regain positive prospects after a major client setback, underscoring a potential entry point for up-sell of platform services, maintenance, and broader enterprise licensing.